BLS Pharmaceuticals Reports Record Revenue in June Quarter; Fiscal 2026 Revenue Hits Top End of Guidance Range
BLS Pharmaceuticals (ASX:BLS) reported record quarterly revenue of AU$22.5 million for the three months through June, up 5% from the previous quarter, according to a Monday filing with the Australian bourse.The quarterly sales brought fiscal 2026 revenue to about AU$75 million, 156% above the previous fiscal year and hitting the top end of the company's guidance range, per the filing.The company further reported record fiscal 2026 adjusted earnings before interest, taxes, depreciation, and amortization of AU$19 million, an increase of 190% from the prior year and also at the top end of its guidance range.Additionally, BLS Pharmaceuticals increased its cash balance to AU$13.3 million at the close of June from AU$8.5 million as of March 31.The company's shares gained over 1% in recent Monday trade.
